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Abstract: Purpose: Presence of distant metastasis is a strong independent predictor of poor survival in patients with 
renal cell carcinoma (RCC). Positron emission tomography using F-18 fluorodeoxyglucose (FDG) has been reported to 
be superior to conventional anatomic imaging modalities for detecting distant metastases from RCC.  
Methods: The authors report the findings of four patients who underwent FDG positron emission tomography / computed 
tomography (PET/CT) at varying periods after radical nephrectomy for RCC.  
Results: FDG PET/CT detected increased tracer concentration in the adrenal glands in all four patients and subsequent 
fine needle aspiration confirmed metastatic RCC. While the adrenal was the only site of metastasis in one patient, 
additional metastases were detected in lymph nodes and lungs in the others.  
Conclusions: RCC metastatic to the adrenal gland is usually a vascular tumour and there is an intrinsic risk of 
haemorrhage during CT-guided needle biopsy. This small series of cases suggests that FDG PET/CT is a useful non-
invasive investigation in identifying malignant adrenal lesions in patients with RCC presenting after nephrectomy.  
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INTRODUCTION 
The role of F-18 fluorodeoxyglucose positron 
emission tomography (FDG PET) in the detection of 
renal cell carcinoma (RCC) is limited by low sensitivity 
[1]. Renal excretion of FDG may hamper the detection 
of renal cell carcinoma. Presence of distant metastasis 
is a strong independent predictor of poor survival in 
patients with RCC. Patients with metastatic disease 
have a 5-year survival rate of 0 to 20% [2-3].
 
A 5-year 
survival rate of 25-50% has been reported for patients 
with solitary metastases from RCC that can be 
completely resected [4-5].
 
Currently available anatomic 
imaging techniques have limited accuracy for the 
detection of distant metastases. The sensitivity of 
computed tomography (CT) for detection of lung 
metastases from extra-thoracic malignancies ranges 
from 75-95% and can be as low as 48-69% for 
metastases less than 6 mm in size [6].
 
FDG PET has 
been reported to be superior to conventional anatomic 
imaging modalities for detecting distant metastases 
from RCC [7]. We report a series of four cases where 
FDG PET/CT was useful in characterising ipsilateral 
and contralateral adrenal lesions in patients with RCC 
at varying periods after nephrectomy. 
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CASE 1 
A 54-year-old man underwent left radical 
nephrectomy for clear cell adenocarcinoma of the left 
kidney (stage T2N0M0). The tumour was 10 cm in size, 
involving the upper pole of the left kidney with no 
capsular invasion and the left adrenal gland was free of 
tumour. He presented to our institute one year later 
with a right adrenal mass and left-sided pleural effusion 
detected on CT imaging of the chest and abdomen. He 
was referred for FDG PET/CT to assess for any 
involvement of the right adrenal gland and any other 
metastasis. The images (Figure 1A-C.) showed a focus 
of FDG uptake in the enlarged right adrenal gland as 
well as in multiple enlarged axillary and mediastinal 
nodes. Fine needle aspiration cytology (Figure 1D.) 
confirmed metastatic RCC. Treatment with Sunitinib 
was started and he is currently on follow up. 
CASE 2 
A 53-year-old man presented with CT scan of the 
chest and abdomen showing a soft tissue density mass 
in relation to the inferior part of the lateral limb of the 
left adrenal gland. He had previously undergone left 
radical nephrectomy 2 years earlier for clear cell 
adenocarcinoma in the mid-part of the left kidney with 
no capsular invasion. FDG PET/CT (Figure 2.) showed 
a focus of tracer uptake in the enlarged left adrenal 
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gland as the only site of involvement, which was 
confirmed as metastasis on CT-guided FNAC. 
 
Figure 1: FDG PET/CT images: the maximum intensity 
projection (MIP) image (A) coronal PET/CT (B) and axial 
PET/CT (C) show a focus of intense tracer uptake (SUVmax 
7.3) in the enlarged right adrenal gland (arrow) and in 
multiple enlarged axillary and mediastinal nodes. Fine needle 
aspiration cytology (D) from the right adrenal gland show a 
cluster of tumor cells with a moderate amount of vacuolated 
cytoplasm, moderate nuclear pleomorphism and prominent 
nucleoli. 
 
Figure 2: FDG PET/CT images: the maximum intensity 
projection (MIP) image (A), coronal PET/CT (B) and axial 
PET/CT (C) show a focus of intense tracer uptake (SUVmax 
8.2) in the enlarged left adrenal gland (arrow) as the only site 
of involvement. 
CASE 3 
A 65 year old man who had undergone right radical 
nephrectomy for clear cell adenocarcinoma 3 years 
previously presented with abdominal pain. He 
underwent CT scan of the abdomen, which showed a 
large lesion in the right adrenal gland. FDG PET/CT 
(Figure 3.) showed intense tracer uptake in the 
enlarged right adrenal gland and multiple mediastinal 
lymph nodes. He was confirmed to have metastasis in 
the adrenal gland on CT-guided FNAC and started on 
chemotherapy. 
 
Figure 3: FDG PET/CT images: the maximum intensity 
projection (mip) image (A) coronal pet/ct (B) and axial pet/ct 
(C) show intense tracer uptake (suvmax 5.2) in the enlarged 
right adrenal gland (arrow) and multiple mediastinal lymph 
nodes. 
CASE 4 
A 74 year old man who underwent radical 
nephrectomy for clear cell adenocarcinoma in the lower 
pole of the left kidney two years ago presented with 
pain in the abdomen. He underwent CT scan of the 
chest and abdomen, which showed a soft tissue lesion 
in the upper lobe of the left lung and another lesion in 
the left adrenal gland. He was referred for FDG 
PET/CT (Figure 4.) to characterize the lung and 
adrenal lesions. FDG PET/CT showed intense tracer 
uptake in the upper lobe of the left lung and the left 
adrenal gland, which was confirmed as metastatic 
RCC. He was started on chemotherapy. 
 
Figure 4: FDG PET/CT images: the maximum intensity 
projection (MIP) image (A), coronal PET/CT (B) and axial 
PET/CT (C) show intense tracer uptake (SUVmax 10.3) in the 
upper lobe of the left lung (arrowhead) and the left adrenal 
gland (arrow). 
DISCUSSION 
Although RCC can metastasize to almost any 
organ, the most common metastatic sites are the lungs, 
abdomen, bones and brain [8]. While metastasis of 
RCC to different sites is not uncommon, contralateral 
adrenal metastasis (CAM) is rare. In one autopsy study 
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of more than 400 patients who had undergone 
nephrectomy for RCC [9], the contralateral adrenal 
gland was the sole site of metastatic involvement in 
only 2.5%. Among those with widespread RCC meta- 
stases identified at autopsy, the contralateral adrenal 
gland was involved in 12.7% of patients. In addition to 
being able to metastasize to different organs, RCC can 
recur many years after resecting the primary tumor 
[10]. In a recent study, a series of 1179 patients were 
treated for RCC and it was found that the global 
incidence of adrenal metastasis among those patients 
was 3.7%, of which 1.9% were ipsilateral, 1.5% contra- 
lateral, 0.3% bilateral, 2.7% synchronous with the renal 
tumor and only 1% metachronous metastasis [11]. 
The behaviour of RCC is unpredictable. Metastasis 
may be found synchronously with the primary tumor or 
in various organs many years after treating the primary 
malignancy. Metastasis of RCC to the contralateral 
adrenal gland has been diagnosed as late as 23 years 
after nephrectomy [11].
 
Adrenal metastases are usually 
anatomically and functionally silent and patients rarely 
have symptoms or signs of adrenal insufficiency. Thus, 
abdominal imaging is not always used routinely during 
the follow-up and an isolated contralateral adrenal 
gland metastasis from RCC is rarely diagnosed during 
life. The underlying biological pathway for secondary 
involvement of the contralateral adrenal gland by RCC 
is unknown. 
The optimal diagnostic approach to a solitary 
contralateral adrenal tumor in patients with a history of 
RCC is controversial and differs from the management 
of adrenal ‘incidentalomas.’ Radiological studies cannot 
determine with certainty whether an adrenal tumor in a 
patient with RCC is a primary adrenal neoplasm (the 
most common type), an adrenal cortical adenoma, or a 
metastasis. In these patients, presence of a solitary 
adrenal tumor with no elevation in serum adrenocortical 
hormones is strongly suggestive of a metastatic lesion 
to the adrenal gland. RCC metastatic to the adrenal 
gland is usually a vascular tumor, compared with the 
more hypovascular adrenal cortical adenoma or 
carcinoma. Biopsy of adrenal masses may be helpful in 
doubtful cases, although in general the diagnosis of 
RCC by biopsy has been problematic [12]. Because of 
the vascular structure of the tumor, there is an intrinsic 
risk of haemorrhage during CT-guided needle biopsy. 
All of our patients underwent FNAC to confirm 
metastasis and they have no complication of 
hemorrhage. The mediastinal lymph node metastasis in 
one of the patient and lung metastasis in another 
patient was confirmed on follow up evaluation. 
The overall sensitivity and specificity of FDG PET 
for detection of primary RCC has been reported to 
range from 31-95% and 33-90%, respectively [1].
 
FDG 
PET has not been extensively studied for evaluation of 
distant metastases from RCC. Reported studies of 
FDG PET in metastatic RCC have involved few 
patients, and most series have compared the results of 
FDG PET with clinical outcome determined by follow-
up with conventional anatomic radiologic techniques. 
Pathologic confirmation of metastatic disease, if 
performed, was usually combined with radiological 
follow-up for reporting results. Using FDG PET for 
restaging 36 patients with advanced RCC, Safaei et al. 
biopsied 25 suspicious lesions from 20 patients and 
demonstrated a sensitivity and specificity of 87% and 
100%, respectively [13]. FDG PET accurately identified 
84% (21 / 25) of the biopsied lesions. FDG PET had an 
overall diagnostic accuracy of 89% for restaging 
residual/recurrent RCC. Park et al. [14] evaluated the 
role of FDG PET/CT for the surveillance of patients 
with RCC who have a high risk of local recurrence or 
distant metastasis, by comparing the results with those 
of conventional imaging methods. Isolated local 
recurrences after radical nephrectomy for renal cell 
carcinoma occur in 2% to 3% of cases. FDG PET/CT 
accurately classified the presence of a recurrence or 
metastasis in 56 (89%) patients. FDG PET/CT showed 
an 89.5% sensitivity, 83.3% specificity, 77.3% positive 
predictive value, 92.6% negative predictive value, and 
85.7% accuracy in detecting recurrence or metastasis, 
which was not significantly different from the results 
with conventional methods. 
CONCLUSION 
RCC metastatic to the adrenal gland is usually a 
vascular tumor, compared with the more hypovascular 
adrenal cortical adenoma or carcinoma. Because of the 
vascular structure of the tumour, there is an intrinsic 
risk of haemorrhage during CT-guided needle biopsy. 
This small series of cases suggests that FDG PET/CT 
is a useful non-invasive investigation in identifying 
malignant adrenal lesions in patients with RCC 
presenting after nephrectomy and avoiding risk of 
biopsy causing hemorrhage. 
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